Niigata Cancer Center Hospital, Niigata, Japan
Masaki Aizawa , Michitaka Honda , Naoki Hiki , Takahiro Kinoshita , Hiroshi Yabusaki , Souya Nunobe , Hidehito Shibasaki , Atsushi Matsuki , Takayuki Abe , Masahiro Watanabe , Atsushi Nashimoto
Background: The aim of this study was to clarify the oncological safety of pylorus-preserving gastrectomy (PPG) compared with conventional distal gastrectomy (DG). Methods: From three institutions specializing in cancer, the medical records for a cohort of 2,898 consecutive patients who had undergone DG (n = 2,208) or PPG (n = 690) for clinical Stage I gastric cancer between January 2006 and December 2012 were analyzed. A propensity score for each patient was estimated based on 38 preoperative clinical and tumor related factors. After propensity score matching, 1,004 patients (DG = 502, PG = 502) were included in the analysis. The overall survival, relapse free survival and occurrence of secondary gastric cancer were then compared. The median (range) observation period was 48.6 (1-109.8) months. Results: The patients who received a PPG were relatively young age (58.7 ± 10.4 years) and had a high performance status, middle gastric tumor, solitary tumor, clinical T1, and clinical N0. The 5-year overall survival was 98.4 % for the PPG group and 96.6% for the DG group (Hazard ratio: 0.48, 95%CI: 0.21 - 1.09, P= 0.07). The 3-year relapse-free survival was 99.5% for the PPG group and 98.0% for the DG group (HR: 0.39, 95%CI: 0.12 – 1.33, P= 0.12). Postoperative secondary gastric cancer was encountered in 8 (1.6 %) in the PPG group and 4 patients (0.8 %) in the DG group. No significant differences in either overall survival, relapse free survival or the occurrence of secondary gastric cancer were observed between the two groups. Conclusions: Given the adequate estimation of the clinical tumor stage, the oncological safety of PPG for clinical T1N0 gastric cancer in the middle stomach was comparable to that of DG.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Ryota Sakon
2023 ASCO Annual Meeting
First Author: Sara M. Tolaney
2024 ASCO Annual Meeting
First Author: ChangSeok Ko
First Author: Salah-Eddin Al-Batran